ICTM logo
A randomised trial of epirubicin and cyclosphamide versus epirubicin and paclitaxel in the treatment of women with metastatic breast cancer
Can a new combination of drugs help to treat people with breast cancer that has spread?
What was this study about?

In the early 1990s doctors usually treated women with breast cancer that had spread to other parts of their body with two chemotherapy drugs – epirubicin and cyclosphamide. But researchers had found that another chemotherapy drug called paclitaxel might be more effective.

The AB01 trial aimed to test whether a new chemotherapy treatment of epirubicin and paclitaxel would be more effective than the usual treatment at that time – epirubicin and cyclosphamide.

Who was included?

705 patients with breast cancer that had spread to other parts of their body. They came from 62 different hospitals.

What difference did this study make?

This trial found that the new chemotherapy treatment was no more effective than the usual chemotherapy treatment.

NICE used the results of this study to recommend that paclitaxel should not be used to treat women with breast cancer that had spread to other parts of their body.

Contact details

When did it take place?

This trial began recruiting patients in 1996 and closed to recruitment in 1999. The results were published in 2005.

Where did it take place?

Who funded the study?

The Medical Research Council, with contributions from the pharmaceutical companies Bristol Myers-Squibb, Pharmacia and Upjohn.

Further information

Type of study:
Randomised trial
Study start date:

Related Publications

Gillessen, S., Attard, G., Beer, T.M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B.H., Clarke, N., Daugaard, G., Davis, I.D., de Bono, J., Borges Dos Reis, R., Drake, C.G., Eeles, R., Efstathiou, E., Evans, C.P., Fanti, S., Feng, F., Fizazi, K., Frydenberg, M., Gleave, M., Halabi, S., Heidenreich, A., Higano, C.S., James, N., Kantoff, P., Kellokumpu-Lehtinen, P.L., Khauli, R.B., Kramer, G., Logothetis, C., Maluf, F., Morgans, A.K., Morris, M.J., Mottet, N., Murthy, V., Oh, W., Ost, P., Padhani, A.R., Parker, C., Pritchard, C.C., Roach, M., Rubin, M.A., Ryan, C., Saad, F., Sartor, O., Scher, H., Sella, A., Shore, N., Smith, M., Soule, H., Sternberg, C.N., Suzuki, H., Sweeney, C., Sydes, M.R., Tannock, I., Tombal, B., Valdagni, R., Wiegel, T., Omlin, .

Management of patients with advanced prostate cancer: the Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Association of Urology. 2018; 73:178-211

Lemanska, A., Dearnaley, D.P., Jena, R., Sydes, M.R., Faithfull, .

Older age, early symptoms and physical function are associated with the severity of late symptom clusters for men undergoing radiotherapy for prostate cancer. Clinical Oncology (Royal College of Radiologists). 2018.

Rydzewska, L.H.M., Burdett, S., Vale, C.L., Parmar, M.K.B., Tierney, J.

Response to letter commenting on published paper: Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. European Journal of Cancer. 2018; 94:218-219

Sydes, M. R., Spears, M. R., Mason, M. D., Clarke, N. W., Dearnaley, D. P., de Bono, J. S., Attard, G., Chowdhury, S., Cross, B., Gillessen, S., Malik, Z., Jones, R., Parker, C., Ritchie, A. W. S., Russell, J. M., Millman, R., Matheson, D., Amos, C., Gilson, C., Birtle, A., Brock, S., Capaldi, L., Chakraborti, P., Choudhury, A., Evans, L., Ford, D., Gale, J., Gibbs, S., Gilbert, D., Hughes, R., McLaren, D., Lester, J., Nikapota, A., O'Sullivan, J., Parikh, O., Peedell, C., Protheroe, A., Rudman, S. M., Shaffer, R., Sheehan, D., Simms, M., Srihari, N., Strebel, R., Sundar, S., Tolan, S., Tsang, D., Varughese, M., Wagstaff, J., Parmar, M. K. B., James, N. .

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncolology. 2018.

Cafferty, F.H., Coyle, C., Rowley, S., Berkman, L., MacKensie, M., Langley, R.

Co-enrolment of participants into multiple cancer trials: benefits and challenges. Clinical Oncology. 2017; 29:e126-e133